🚨 SUN PHARMA: Positive Oncology Development

Sun Pharma's UNLOXCYT® has received a Category 2A recommended designation in updated NCCN Guidelines for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients ineligible for curative surgery or radiation. 🔹 Clinical data: 55% objective response rate; 26% complete response rate in the pivotal study. 🔹 Potential impact: Improved treatment access and stronger positioning in the US specialty oncology market. 💡 AFS Investor Insight: A positive clinical milestone, but its financial impact will depend on commercial adoption and revenue contribution. Like | Share | Follow AFS Trading Edge for investor-focused market insights. Disclaimer: For educational and informational purposes only. Not investment advice or a recommendation to buy, sell or hold any security.